利伐沙班治疗慢性阻塞性肺疾病急性加重期的效果观察

目的探讨利伐沙班治疗慢性阻塞性肺疾病急性加重期的临床治疗效果。方法选择2011年3月至2013年3月慢性阻塞性肺疾病急性加重期患者120例，按随机数字表法分成观察组和对照组，各60例。2组均给予抗生素抗感染、支气管扩张剂、祛痰、持续低流量吸氧等常规治疗，观察组在此基础上加用利伐沙班10mg，口服，1次／d，共7d，观察2组疗效。结果观察组有效率[83．3％（50／60）]高于对照组（53．3％，32／60），平均住院时间[（10．5±2．4）d]短于对照组[（18．5±5．6）d]，差异均有统计学意义（均P〈0．01）。观察组治疗后凝血功能改善情况优于对照组（P〈0．01或P〈0．05）；D-二聚体与治疗前及对照组治疗后比较差异均有统计学意义[（1．1±0．9）mg／L比（2．6±0．4），（2．5±1．0）mg／L]（均P〈0．01），观察组治疗前后血气分析改善程度与对照组比较差异有统计学意义（P〈0．05）。结论利伐沙班抗凝治疗慢性阻塞性肺疾病急性加重期疗效肯定，能明显减轻患者血液高凝状态，减轻炎症反应，延缓病情进展。

Clinical effect of rivarxocaban in the treatment of acute exacerbation of chronic obstructive pulmonary disease

Objective To discuss the clinical effect of rivarxocaban in the treatment of acute exacerbations of the acute exacerbation of chronic obstructive pulmonary disease （AECOPD）. Methods One hundred and twenty cases with AECOPD from March 2011 to March 2013 were randomly divided into observation group（ 60 cases ） and control group（60 cases）. Both groups received conventional treatment including antibiotics, bronehodilator, phlegm removing and continuous low-flow oxygen inhalation. The observation group received rivarxocaban take orally（ 10 mg） per 24 hours for 7 days of two groups were observed. Results The total effective rate of the observation group was 83.3% （50/60） ,which was higher than that in control group（ 53.3%, 32/60）, the average hospitalization time of the observation group was （ 10.5 ± 2.4） d, which was shorter than （ 18.5 ± 5.6 ） d in control group （ P 〈 0.01 ）. Compared with control group, the observation group＇s blood coagulation and blood gas analysis were improved（ P 〈 0.01 or P 〈 0.05 ）. D-eimer level dropped, the difference was significant （ P 〈 0.01 ）. Conclusion Rivarxocaban has a definite effect on AECOPD and it can effectively improve the blood hypercoagulable state and clinical symptoms, alleviate the inflammation reaction and defer the worsening of illness.